Novaliq Gmbh patents expiration
1. Vevye patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8614178 | NOVALIQ GMBH | Pharmaceutical composition for treatment of dry eye syndrome |
Dec, 2030
(7 years from now) | |
| US10813976 | NOVALIQ GMBH | Ophthalmic compositions comprising ciclosporin |
Sep, 2037
(13 years from now) | |
| US11154513 | NOVALIQ GMBH | Semifluorinated compounds |
Nov, 2038
(15 years from now) | |
| US11413323 | NOVALIQ GMBH | Ophthalmic composition for treatment of dry eye disease |
Oct, 2039
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 30, 2026 |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 30 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of dry eye disease (ded)
Dosage: SOLUTION;OPHTHALMIC
More Information on Dosage
VEVYE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic